Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.5.106NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.106NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.106NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.106NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.5.106ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.5.11ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.5.11ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.11NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.5.11NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.11NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.11NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.11NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-893.215Hong Kong
XBB.1.5.11ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FE.1.1.2ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FE.1.1.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FE.1.1.2NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FE.1.1.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FE.1.1.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FE.1.1.2NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FE.1.1.2NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FE.1.1.2ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FY.4.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FY.4.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FY.4.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FY.4.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FY.4.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FY.4.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FY.4.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FY.4.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
GZ.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
GZ.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GZ.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
GZ.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GZ.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GZ.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
GZ.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
GZ.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FT.3.1.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FT.3.1.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FT.3.1.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FT.3.1.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FT.3.1.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FT.3.1.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FT.3.1.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FT.3.1.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
EG.4.4ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
EG.4.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
EG.4.4NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
EG.4.4NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
EG.4.4NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used